
Commentary|Articles|December 12, 2014
Toxicities Associated With PI3K Inhibitors
Author(s)Denise A. Yardley, MD
Denise A. Yardley, MD, from Sarah Cannon Research Institute, discusses toxicities associated with treatment with PI3K inhibitors for breast cancer.
Advertisement
Denise A. Yardley, MD, from Sarah Cannon Research Institute, discusses toxicities associated with treatment with PI3K inhibitors for breast cancer.
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
3
CheckMate 9LA Data Push Toward Dual Checkpoint Blockade in PD-L1–Negative NSCLC
4
Thoracic Radiotherapy Added to Atezolizumab Raised Toxicity in SCLC
5



























